Is Lymphadenectomy Reasonable for Elderly Intrahepatic Cholangiocarcinoma Patients?

被引:1
|
作者
Lin, Qianyi [1 ]
Chen, Jianjun [2 ]
Li, Kangde [1 ]
Yang, Junxing [3 ]
Luo, Xiaofeng [3 ]
Cai, Qi [1 ]
Lin, Weihong [1 ]
Peng, Guanjing [1 ]
Chen, Dexiong [1 ]
Qin, Chunhong [1 ]
He, Tao [1 ]
Wang, Zhenlong [3 ]
机构
[1] Guangdong Med Univ, Cent Peoples Hosp Zhanjiang, Zhanjiang Cent Hosp, Dept Gen Surg 6, Zhanjiang, Guangdong, Peoples R China
[2] Guangdong Med Univ, Cent Peoples Hosp Zhanjiang, Zhanjiang Cent Hosp, Dept Gen Surg 2, Zhanjiang, Guangdong, Peoples R China
[3] Guangdong Med Univ, Cent Peoples Hosp Zhanjiang, Zhanjiang Cent Hosp, Dept Gen Surg 7, Zhanjiang, Guangdong, Peoples R China
关键词
Intrahepatic cholangiocarcinoma; Elderly; Lymphadenectomy; Perioperative mortality; Overall survival; LYMPH-NODE DISSECTION; POSTOPERATIVE COMPLICATIONS; HEPATOCELLULAR-CARCINOMA; RESECTION; MANAGEMENT;
D O I
10.1007/s11605-023-05846-y
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background In this study, we aimed to determine the impact of lymphadenectomy (LND) on clinical outcomes in ICC patients aged >= 70 years.Methods Four hundred and three eligible patients diagnosed with ICC who underwent hepatectomy between 2004 and 2019 were enrolled in the Surveillance, Epidemiology, and End Results database. The impact of LND on perioperative mortality and overall survival (OS) as well as the optimal total number of lymph nodes examined (TNLE) was estimated.Results One hundred thirty-nine pairs of patients were matched by propensity score matching. Perioperative mortality was comparable between the LND and non-LND (nLND) groups (0.7% vs. 2.9%, P = 0.367). The median OS in the LND group was significantly longer (44 vs. 32 months, P = 0.045) and LND was identified as an independent protective factor for OS by multivariate analysis (HR 0.65, 95% CI 0.46-0.92, P = 0.014). Patients with the following characteristics were potential beneficiaries of LND: white, female, no/moderate fibrosis, tumor size > 5 cm, solitary tumor, and localized invasion (all P < 0.05). TNLE >= 6 had the greatest discriminatory power for identifying lymph node metastasis (area under the curve, 0.704, Youden index, 0.365, P = 0.002). Patients with pathologically confirmed lymph node metastasis are likely to benefit from adjuvant therapy (40 months vs. 4 months, P = 0.052).Conclusions Advanced age (>= 70 years) was not a contraindication for LND, which facilitates accurate nodal staging and guides postoperative management. Appropriately selected elderly populations could benefit from LND.
引用
收藏
页码:2451 / 2463
页数:13
相关论文
共 50 条
  • [21] Defining the Possible Therapeutic Benefit of Lymphadenectomy Among Patients Undergoing Hepatic Resection for Intrahepatic Cholangiocarcinoma
    Vitale, Alessandro
    Moustafa, Mohamed
    Spolverato, Gaya
    Gani, Faiz
    Cillo, Umberto
    Pawlik, Timothy M.
    JOURNAL OF SURGICAL ONCOLOGY, 2016, 113 (06) : 685 - 691
  • [22] Surgical Management of Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Impact of Lymphadenectomy on Peri-Operative Outcomes
    Fabio Bagante
    Gaya Spolverato
    Matthew Weiss
    Sorin Alexandrescu
    Hugo P. Marques
    Luca Aldrighetti
    Shishir K. Maithel
    Carlo Pulitano
    Todd W. Bauer
    Feng Shen
    George A. Poultsides
    Olivier Soubrane
    Guillaume Martel
    B. Groot Koerkamp
    Alfredo Guglielmi
    Endo Itaru
    Andrea Ruzzenente
    Timothy M. Pawlik
    World Journal of Surgery, 2018, 42 : 2551 - 2560
  • [23] We Asked the Experts: Role of Lymphadenectomy in Surgical Management of Intrahepatic Cholangiocarcinoma
    Hassan Aziz
    Timothy M. Pawlik
    World Journal of Surgery, 2023, 47 : 1530 - 1532
  • [24] Should Utilization of Lymphadenectomy Vary According to Morphologic Subtype of Intrahepatic Cholangiocarcinoma?
    Zhang, Xu-Feng
    Lv, Yi
    Weiss, Matthew
    Popescu, Irinel
    Marques, Hugo P.
    Aldrighetti, Luca
    Maithel, Shishir K.
    Pulitano, Carlo
    Bauer, Todd W.
    Shen, Feng
    Poultsides, George A.
    Soubrane, Oliver
    Martel, Guillaume
    Koerkamp, B. Groot
    Itaru, Endo
    Pawlik, Timothy M.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (07) : 2242 - 2250
  • [25] Should Utilization of Lymphadenectomy Vary According to Morphologic Subtype of Intrahepatic Cholangiocarcinoma?
    Xu-Feng Zhang
    Yi Lv
    Matthew Weiss
    Irinel Popescu
    Hugo P. Marques
    Luca Aldrighetti
    Shishir K. Maithel
    Carlo Pulitano
    Todd W. Bauer
    Feng Shen
    George A. Poultsides
    Oliver Soubrane
    Guillaume Martel
    B. Groot Koerkamp
    Endo Itaru
    Timothy M. Pawlik
    Annals of Surgical Oncology, 2019, 26 : 2242 - 2250
  • [26] We Asked the Experts: Role of Lymphadenectomy in Surgical Management of Intrahepatic Cholangiocarcinoma
    Aziz, Hassan
    Pawlik, Timothy M.
    WORLD JOURNAL OF SURGERY, 2023, 47 (06) : 1530 - 1532
  • [27] ASO Author Reflections: Which Patients Benefit the Most From Lymphadenectomy During Resection for Intrahepatic Cholangiocarcinoma?
    Sahara, Kota
    Tsilimigras, Diamantis, I
    Pawlik, Timothy M.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (09) : 2969 - 2970
  • [28] Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node negative intrahepatic cholangiocarcinoma
    Magyar, Christian Tibor Josef
    Beldi, Guido
    Banz, Vanessa
    JOURNAL OF HEPATOLOGY, 2023, 78 (05) : E169 - E170
  • [29] Dynamic evaluation of postoperative survival in intrahepatic cholangiocarcinoma patients who did not undergo lymphadenectomy: a multicenter study
    Huang, Tingfeng
    Kong, Jie
    Liu, Hongzhi
    Lin, Zhipeng
    Lin, Qizhu
    Lou, Jianying
    Zheng, Shuguo
    Bi, Xinyu
    Wang, Jianming
    Guo, Wei
    Li, Fuyu
    Wang, Jian
    Zheng, Yamin
    Li, Jingdong
    Cheng, Shi
    Zhou, Weiping
    Zeng, Yongyi
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2023, 58 (02) : 178 - 184
  • [30] ASO Author Reflections: Which Patients Benefit the Most From Lymphadenectomy During Resection for Intrahepatic Cholangiocarcinoma?
    Kota Sahara
    Diamantis I. Tsilimigras
    Timothy M. Pawlik
    Annals of Surgical Oncology, 2019, 26 : 2969 - 2970